Clinical Trials Browser

Phase 2 × Completed × Triple Negative Breast Neoplasms × Clear all

NCT02595905 2026-04-08

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

Phase 2 Completed

344 enrolled 11 charts

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT05340413 2026-03-16

RADIOLA

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04191135 2026-03-03

KEYLYNK-009

Phase 2 Completed

462 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Phase 2 Completed

37 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT03301350 2026-02-13

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Phase 2 Completed

29 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04758780 2026-02-05

OPALESCENCE

Phase 2 Completed

12 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT04699630 2025-12-22

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05001347 2025-12-16

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Phase 2 Completed

25 enrolled 11 charts

BreastGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05520723 2025-12-04

PRIMED

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03797326 2025-11-17

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02593175 2025-11-06

Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC

Phase 2 Completed

43 enrolled 8 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03620643 2025-10-30

ROLo

Phase 2 Completed

33 enrolled 13 charts

BreastGastrointestinal

Stomach Neoplasms, Carcinoma, Lobular, Triple Negative Breast Neoplasms

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01982448 2025-09-30

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

Phase 2 Completed

147 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT07143097 2025-08-27

Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05632848 2025-07-21

Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT06355024 2025-07-18

Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT01818063 2025-04-30

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2 Completed

9 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01349959 2025-04-27

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

Phase 2 Completed

58 enrolled 16 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02423603 2025-03-10

PAKT

Phase 2 Completed

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT06618014 2025-01-16

NeoTOP

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03206203 2024-12-12

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Phase 2 Completed

106 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03487666 2024-12-03

OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease

Phase 2 Completed

45 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT04111510 2024-11-21

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

Phase 2 Completed

6 enrolled 13 charts

Triple Negative Breast Neoplasms

NCT03004183 2024-10-15

STOMP

Phase 2 Completed

57 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT03164993 2024-10-15

ALICE

Phase 2 Completed

Breast Neoplasms, Neoplasms, Triple Negative Breast Neoplasms

NCT02187991 2024-10-09

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Phase 2 Completed

169 enrolled 15 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04664972 2024-09-20

Comparison of TP and TAC Regimens in Neoadjuvant Treatment of TNBC

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT02689427 2024-09-19

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

Phase 2 Completed

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04464174 2024-07-26

PATHFINDER

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT02981303 2024-07-09

Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

Phase 2 Completed

64 enrolled 17 charts

Triple Negative Breast Neoplasms

NCT04408118 2024-06-04

ATRACTIB

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Phase 2 Completed

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05112536 2024-03-12

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Phase 2 Completed

24 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02971761 2024-02-20

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Phase 2 Completed

18 enrolled 17 charts

Triple Negative Breast Neoplasms

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase 2 Completed

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT04596150 2024-01-23

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Phase 2 Completed

Breast Neoplasms, Neoplasms, Triple Negative Breast Neoplasms

NCT02527434 2023-11-15

Study of Tremelimumab in Patients With Advanced Solid Tumors

Phase 2 Completed

64 enrolled 22 charts

Triple Negative Breast Neoplasms

NCT03358017 2023-10-19

YAPPETIZER

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT03121352 2023-10-06

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Phase 2 Completed

30 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT04032080 2023-09-11

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

Phase 2 Completed

10 enrolled 9 charts

Triple Negative Breast Neoplasms

NCT03193853 2023-08-07

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

Phase 2 Completed

12 enrolled 11 charts

Triple Negative Breast Neoplasms

NCT00679783 2023-07-12

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

Phase 2 Completed

99 enrolled 17 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02768701 2023-05-22

Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer

Phase 2 Completed

40 enrolled 17 charts

Triple Negative Breast Neoplasms

NCT02401347 2023-02-21

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Phase 2 Completed

21 enrolled 12 charts

Triple Negative Breast Neoplasms

NCT04320030 2023-02-21

EITHICS

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT03499899 2023-01-30

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

Phase 2 Completed

88 enrolled 35 charts

Triple Negative Breast Neoplasms

NCT03057600 2022-09-28

Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

Phase 2 Completed

52 enrolled 16 charts

Triple Negative Breast Neoplasms